Don’t let them tell you otherwise
Unsubscribe | Report as spam | Change email preferences
This increases the risk of prostate cancer
The development of the prostate – its early growth – depends on male hormones testosterone and DHT.
This is one of the reasons that male hormones have been erroneously blamed for prostate problems including prostate cancer.
But every time we look at the relationship between these hormones and prostate cancer in the real world we see just the opposite.
Testosterone and DHT levels are inversely related to prostate cancer risk. Let’s take a look at this study which looked at the relationship between testosterone and prostate cancer.
The human research was carried out at Hospital Clinic de Barcelona in Spain. The paper was published in BJUI Urological Oncology.
Cancer is essentially uncontrolled growth of cells. The growth of prostate cells in early development are dependent on testosterone.
“Prostate growth is ruled by testosterone.”
This might seem to indicate that testosterone could cause uncontrolled growth of prostate cells – cancer. It’s a widely held belief – but it’s not supported by the evidence.
Growth in development is not the same as uncontrolled growth.
“The paradigm that high testosterone levels induce prostate cancer development or lead to a poor prognosis in prostate cancer is not supported by evidence.”
In fact, there is stronger evidence to indicate that low levels of testosterone increase the risk of prostate cancer.
“A growing number of studies suggest that low testosterone levels are related to poor prognosis features in prostate cancer such as higher prostate-specific antigen or higher Gleason score.”
The authors of this study had noted that in their treatment of men with prostate cancer there seemed to be a relationship between lower testosterone and greater risk.
“Our experience shows that those men with lower testosterone levels are at higher risk of progression of their prostate cancer after treatment delivery.”
They decided to analyze the data to see whether their observations were correct.
“We analyzed 137 males diagnosed in our center with prostate cancer with prostate biopsies from February 2007 to December 2009.”
They already had information on testosterone levels from the men that they treated – as this was standard clinical protocol.
“As part of our clinical protocol, we performed hormonal determination (testosterone and sex hormone binding globulin) following international recommendations.”
They also had information on a lot of prostate -related markers. This includes the PSA – a marker of general inflammation in the prostate.
The researchers also had information on Gleason score – a rating of cancer severity based on biopsies.
“PSA, number of previous biopsies, digital rectal examination staging, Gleason score, percentage of tumour in the biopsy sample, bilaterality of the tumour and risk of progression group were prospectively recorded.”
The data seemed to confirm their observations. Higher testosterone was associated with lower risk of more advanced prostate cancer.
“Higher testosterone levels were related to lower digital rectal examination staging and lower PSA level.”
The Gleason score – analysis of prostate biopsies – is probably the best marker of prostate cancer severity. But the researchers found no relationship with testosterone and Gleason scores.
“Higher testosterone was not related to lower Gleason score.”
In most of the analyses, it was clear that lower testosterone was associated with greater risk.
“Testosterone was inversely related to prostate cancer bilaterality and percentage of tumor in the biopsy.”
Men who had been allocated to a low risk group based on their test results tended to have higher testosterone.
“High testosterone levels were found in patients allocated to the low risk of progression group and inversely.”
The researchers also showed that men who had lower testosterone levels were more likely to have recurrence of prostate cancer in the future.
“Patients with prostate cancer and lower testosterone levels have poor prognosis factors and higher tumor burden before treatment onset.”
This study doesn’t show causality – although other studies show that testosterone is protective against prostate cancer – provided it doesn’t get converted into estrogen.
“These findings reinforce the idea that low testosterone levels pretreatment are related to a poor prognosis in prostate cancer.”
You should always consult your healthcare practitioner for guidance on medical diagnosis and treatment.
—-Important Message—-
Prostates do not swell up from testosterone
For instance, I’ve found men with higher testosterone levels have smaller, healthier prostates.
They pee like racehorses and they perform excellently with their wives and girlfriends.
The key is stopping aromatization from happening so rapidly.
And I’ve found a really simple way to do that and it shrinks the prostate down to normal size fast.
Here it is — how to slow down aromatization and prevent a swollen prostate
———-
